Standard BioTools (NASDAQ:LAB) Director Casdin Partners Master Fund, L Acquires 150,000 Shares

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L acquired 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was purchased at an average price of $1.45 per share, with a total value of $217,500.00. Following the completion of the acquisition, the director directly owned 72,100,000 shares of the company’s stock, valued at $104,545,000. This represents a 0.21% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Tuesday, December 2nd, Casdin Partners Master Fund, L acquired 125,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.42 per share, for a total transaction of $177,500.00.
• On Wednesday, December 3rd, Casdin Partners Master Fund, L acquired 75,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.44 per share, with a total value of $108,000.00.
• On Tuesday, November 25th, Casdin Partners Master Fund, L bought 7,550,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.30 per share, with a total value of $9,815,000.00.
• On Monday, November 24th, Casdin Partners Master Fund, L bought 150,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.43 per share, for a total transaction of $214,500.00.
• On Thursday, November 20th, Casdin Partners Master Fund, L purchased 450,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.30 per share, with a total value of $585,000.00.
• On Wednesday, November 19th, Casdin Partners Master Fund, L acquired 350,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.28 per share, with a total value of $448,000.00.
• On Tuesday, November 18th, Casdin Partners Master Fund, L acquired 275,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.23 per share, for a total transaction of $338,250.00.
• On Monday, November 17th, Casdin Partners Master Fund, L bought 225,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.22 per share, for a total transaction of $274,500.00.
• On Friday, November 14th, Casdin Partners Master Fund, L purchased 250,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.24 per share, with a total value of $310,000.00.
• On Thursday, November 13th, Casdin Partners Master Fund, L purchased 450,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.20 per share, for a total transaction of $540,000.00.

Standard BioTools Stock Up 3.8%

Shares of Standard BioTools stock traded up $0.06 on Friday, reaching $1.50. The stock had a trading volume of 135,648 shares, compared to its average volume of 1,692,736. The stock has a market capitalization of $574.92 million, a P/E ratio of -4.40 and a beta of 1.24. The company has a 50 day moving average price of $1.30 and a 200 day moving average price of $1.26. Standard BioTools Inc. has a 1 year low of $0.92 and a 1 year high of $2.25.

Institutional Trading of Standard BioTools

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mak Capital One LLC increased its holdings in shares of Standard BioTools by 184.6% in the third quarter. Mak Capital One LLC now owns 15,931,806 shares of the company’s stock valued at $20,711,000 after purchasing an additional 10,334,384 shares during the period. Long Focus Capital Management LLC purchased a new stake in Standard BioTools in the first quarter valued at approximately $7,236,000. Casdin Capital LLC boosted its position in Standard BioTools by 1.9% in the third quarter. Casdin Capital LLC now owns 77,558,856 shares of the company’s stock valued at $100,827,000 after buying an additional 1,483,220 shares during the last quarter. Kent Lake PR LLC acquired a new position in Standard BioTools in the 2nd quarter worth approximately $1,200,000. Finally, Nuveen LLC purchased a new position in Standard BioTools during the 1st quarter worth approximately $862,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LAB. TD Cowen reduced their price target on Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research report on Wednesday, November 5th. Wall Street Zen lowered Standard BioTools from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Standard BioTools in a report on Wednesday, October 8th. Finally, Cowen lowered Standard BioTools from a “buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Standard BioTools has a consensus rating of “Reduce” and a consensus price target of $1.35.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.